NEO Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-04-08 | 2022 | Melody Harris President, Enterprise Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024-04-08 | 2023 | Melody Harris President, Enterprise Operations | 525,000 | 0 | 1,880,389 | 532,700 | 342,585 | 4,694,225 |
| 2024-04-08 | 2021 | Jeffrey Sherman Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024-04-08 | 2022 | Jeffrey Sherman Chief Financial Officer | 16,154 | 250,000 | 1,500,000 | 0 | 0 | 3,266,154 |
| 2024-04-08 | 2023 | Jeffrey Sherman Chief Financial Officer | 525,000 | 0 | 1,619,944 | 627,000 | 13,200 | 3,547,358 |
| 2024-04-08 | 2022 | Christopher Smith Director and Chief Executive Officer | 346,154 | 0 | 7,600,000 | 455,438 | 2,146,930 | 14,798,522 |
| 2024-04-08 | 2021 | Christopher Smith Director and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024-04-08 | 2021 | Vishal Sikri President, Advanced Diagnostics | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024-04-08 | 2022 | Vishal Sikri President, Advanced Diagnostics | 294,231 | 500,000 | 1,250,000 | 255,000 | 12,750 | 3,561,981 |
| 2024-04-08 | 2023 | Vishal Sikri President, Advanced Diagnostics | 528,635 | 0 | 880,390 | 535,300 | 13,200 | 2,371,776 |
| 2024-04-08 | 2021 | Warren Stone President, Clinical Services | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024-04-08 | 2023 | Christopher Smith Director and Chief Executive Officer | 1,000,000 | 0 | 5,986,768 | 1,850,000 | 12,308 | 11,665,946 |
| 2024-04-08 | 2022 | Warren Stone President, Clinical Services | 40,385 | 350,000 | 1,000,000 | 0 | 0 | 2,390,385 |
| 2024-04-08 | 2023 | Warren Stone President, Clinical Services | 525,000 | 0 | 1,030,398 | 546,800 | 343,669 | 3,009,250 |
| 2024-04-08 | 2021 | Melody Harris President, Enterprise Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2020 | Mark Mallon Former Director and Former Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2022 | Jeffrey Sherman Chief Financial Officer | 16,154 | 250,000 | 1,500,000 | 0 | 0 | 3,266,154 |
| 2023-04-07 | 2021 | Jeffrey Sherman Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2020 | Jeffrey Sherman Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2022 | William Bonello Former Chief Financial Officer | 462,115 | 0 | 330,802 | 0 | 682,500 | 1,552,381 |
| 2023-04-07 | 2021 | William Bonello Former Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2020 | William Bonello Former Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2022 | Warren Stone President, Clinical Services | 40,385 | 350,000 | 1,000,000 | 0 | 0 | 2,390,385 |
| 2023-04-07 | 2021 | Warren Stone President, Clinical Services | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2020 | Warren Stone President, Clinical Services | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2022 | Vishal Sikri President, Advanced Diagnostics | 294,231 | 500,000 | 1,250,000 | 255,000 | 12,750 | 3,561,981 |
| 2023-04-07 | 2021 | Vishal Sikri President, Advanced Diagnostics | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2021 | Dr. Shashikant Kulkarni Chief Scientific Officer and Executive Vice President of Research & Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2020 | Vishal Sikri President, Advanced Diagnostics | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2022 | Dr. Shashikant Kulkarni Chief Scientific Officer and Executive Vice President of Research & Development | 354,808 | 100,000 | 1,000,000 | 187,437 | 27,000 | 2,669,245 |
| 2023-04-07 | 2020 | Dr. Shashikant Kulkarni Chief Scientific Officer and Executive Vice President of Research & Development | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2022 | Christopher Smith Director and Chief Executive Officer | 346,154 | 0 | 7,600,000 | 455,438 | 2,146,930 | 14,798,522 |
| 2023-04-07 | 2021 | Christopher Smith Director and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2020 | Christopher Smith Director and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2022 | Lynn Tetrault Former Interim Chief Executive Officer and Current Chair of the Board of Directors | 391,184 | 0 | 126,000 | 1,500,000 | 0 | 2,071,184 |
| 2023-04-07 | 2021 | Lynn Tetrault Former Interim Chief Executive Officer and Current Chair of the Board of Directors | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2020 | Lynn Tetrault Former Interim Chief Executive Officer and Current Chair of the Board of Directors | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023-04-07 | 2022 | Mark Mallon Former Director and Former Chief Executive Officer | 171,346 | 0 | 3,661,641 | 0 | 1,577,000 | 7,695,856 |
| 2023-04-07 | 2021 | Mark Mallon Former Director and Former Chief Executive Officer | 487,981 | 0 | 7,750,000 | 0 | 83,974 | 11,071,955 |
| 2022-04-14 | 2020 | Kathryn B. McKenzie Chief Financial Officer | 359,616 | 0 | 165,000 | 175,000 | 0 | 1,034,616 |
| 2022-04-14 | 2019 | Mark W. Mallon Director and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-04-14 | 2021 | Douglas M. VanOort Former Chair of the Board and Former Chief Executive Officer | 649,327 | 0 | 1,665,204 | 0 | 0 | 7,227,002 |
| 2022-04-14 | 2020 | Douglas M. VanOort Former Chair of the Board and Former Chief Executive Officer | 669,039 | 0 | 990,000 | 450,000 | 0 | 4,119,039 |
| 2022-04-14 | 2019 | Douglas M. VanOort Former Chair of the Board and Former Chief Executive Officer | 665,000 | 0 | 742,507 | 900,000 | 0 | 3,645,732 |
| 2022-04-14 | 2021 | Mark W. Mallon Director and Chief Executive Officer | 487,981 | 0 | 7,750,000 | 407,900 | 83,974 | 11,479,855 |
| 2022-04-14 | 2020 | Mark W. Mallon Director and Chief Executive Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-04-14 | 2019 | Dr. Clive D. Morris President, Inivata | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-04-14 | 2020 | Dr. Clive D. Morris President, Inivata | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-04-14 | 2021 | Dr. Clive D. Morris President, Inivata | 299,433 | 100,000 | 1,466,667 | 296,900 | 30,185 | 3,126,518 |
| 2022-04-14 | 2019 | Halley E. Gilbert Chief Legal Officer and Corporate Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-04-14 | 2020 | Halley E. Gilbert Chief Legal Officer and Corporate Secretary | 0 | 0 | 0 | 0 | 0 | 0 |
| 2022-04-14 | 2021 | Halley E. Gilbert Chief Legal Officer and Corporate Secretary | 160,885 | 100,000 | 4,000,000 | 84,500 | 100,000 | 5,445,385 |
| 2022-04-14 | 2019 | George A. Cardoza President and Chief Operating Officer, Laboratory Operations, Clinical Services | 380,000 | 0 | 164,993 | 265,000 | 0 | 1,107,374 |
| 2022-04-14 | 2020 | George A. Cardoza President and Chief Operating Officer, Laboratory Operations, Clinical Services | 384,630 | 0 | 214,500 | 155,000 | 0 | 1,189,630 |
| 2022-04-14 | 2021 | George A. Cardoza President and Chief Operating Officer, Laboratory Operations, Clinical Services | 447,500 | 100,000 | 2,660,000 | 242,600 | 10,400 | 4,800,500 |
| 2022-04-14 | 2019 | Kathryn B. McKenzie Chief Financial Officer | 250,000 | 0 | 44,551 | 150,000 | 0 | 524,844 |
| 2022-04-14 | 2021 | Kathryn B. McKenzie Chief Financial Officer | 415,384 | 200,000 | 1,330,000 | 166,500 | 11,600 | 2,793,484 |
| 2021-04-15 | 2018 | Sharon A. Virag Chief Financial Officer | 298,462 | 120,000 | 0 | 190,000 | 0 | 1,093,562 |
| 2021-04-15 | 2020 | Robert J. Shovlin President of Clinical Services | 404,808 | 0 | 247,500 | 140,000 | 3,000 | 1,297,308 |
| 2021-04-15 | 2019 | Robert J. Shovlin President of Clinical Services | 400,000 | 0 | 214,502 | 280,000 | 3,000 | 1,284,099 |
| 2021-04-15 | 2018 | Robert J. Shovlin President of Clinical Services | 375,385 | 0 | 0 | 212,756 | 3,000 | 1,328,739 |
| 2021-04-15 | 2020 | Douglas M. Brown Chief Strategy and Corporate Development Officer | 346,154 | 0 | 198,000 | 200,000 | 100,000 | 1,246,154 |
| 2021-04-15 | 2019 | Douglas M. Brown Chief Strategy and Corporate Development Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-15 | 2018 | Douglas M. Brown Chief Strategy and Corporate Development Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-15 | 2019 | Douglas M. VanOort Chairman of the Board & Chief Executive Officer | 665,000 | 0 | 742,507 | 900,000 | 3,000 | 3,648,732 |
| 2021-04-15 | 2018 | Douglas M. VanOort Chairman of the Board & Chief Executive Officer | 641,923 | 0 | 650,006 | 774,000 | 3,000 | 3,347,219 |
| 2021-04-15 | 2020 | Kathryn B. McKenzie Chief Financial Officer | 359,616 | 0 | 165,000 | 175,000 | 0 | 1,034,616 |
| 2021-04-15 | 2020 | Douglas M. VanOort Chairman of the Board & Chief Executive Officer | 669,039 | 0 | 990,000 | 450,000 | 3,000 | 4,122,039 |
| 2021-04-15 | 2018 | Kathryn B. McKenzie Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-15 | 2018 | Dr. Lawrence M. Weiss Chief Medical Officer | 571,519 | 100,000 | 0 | 32,276 | 0 | 855,895 |
| 2021-04-15 | 2019 | Dr. Lawrence M. Weiss Chief Medical Officer | 600,000 | 0 | 115,503 | 260,000 | 0 | 1,183,674 |
| 2021-04-15 | 2020 | Dr. Lawrence M. Weiss Chief Medical Officer | 600,000 | 0 | 165,000 | 185,000 | 0 | 1,285,000 |
| 2021-04-15 | 2019 | Kathryn B. McKenzie Chief Financial Officer | 250,000 | 0 | 44,551 | 150,000 | 0 | 524,844 |
| 2021-04-15 | 2020 | Sharon A. Virag Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2021-04-15 | 2019 | Sharon A. Virag Chief Financial Officer | 257,723 | 0 | 214,502 | 182,823 | 0 | 1,041,645 |
| 2020-04-15 | 2018 | Robert J. Shovlin President of Clinical Services | 375,385 | 0 | 0 | 212,756 | 3,000 | 1,328,739 |
| 2020-04-15 | 2017 | Robert J. Shovlin President of Clinical Services | 350,000 | 0 | 363,500 | 95,000 | 3,000 | 1,304,167 |
| 2020-04-15 | 2019 | Lawrence M. Weiss Chief Medical Officer | 600,000 | 0 | 115,503 | 260,000 | 0 | 1,183,674 |
| 2020-04-15 | 2018 | Douglas M. VanOort Chairman of the Board & Chief Executive Officer | 641,923 | 0 | 650,006 | 774,000 | 3,000 | 3,347,219 |
| 2020-04-15 | 2019 | Douglas M. VanOort Chairman of the Board & Chief Executive Officer | 665,000 | 0 | 742,507 | 900,000 | 3,000 | 3,648,732 |
| 2020-04-15 | 2017 | Lawrence M. Weiss Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-04-15 | 2018 | Lawrence M. Weiss Chief Medical Officer | 571,519 | 100,000 | 0 | 32,276 | 0 | 855,895 |
| 2020-04-15 | 2017 | Douglas M. VanOort Chairman of the Board & Chief Executive Officer | 616,346 | 0 | 1,432,495 | 200,000 | 3,000 | 3,483,508 |
| 2020-04-15 | 2019 | Sharon A. Virag Chief Financial Officer | 257,723 | 0 | 214,502 | 182,823 | 0 | 1,041,645 |
| 2020-04-15 | 2018 | Sharon A. Virag Chief Financial Officer | 298,462 | 120,000 | 0 | 190,000 | 0 | 1,093,562 |
| 2020-04-15 | 2017 | Sharon A. Virag Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-04-15 | 2019 | Kathryn B. McKenzie Vice President and Chief Accounting Officer (Principal Financial Officer) | 250,000 | 0 | 44,551 | 150,000 | 0 | 524,844 |
| 2020-04-15 | 2018 | Kathryn B. McKenzie Vice President and Chief Accounting Officer (Principal Financial Officer) | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-04-15 | 2017 | Kathryn B. McKenzie Vice President and Chief Accounting Officer (Principal Financial Officer) | 0 | 0 | 0 | 0 | 0 | 0 |
| 2020-04-15 | 2019 | George A. Cardoza President of Pharma Services | 380,000 | 0 | 164,993 | 265,000 | 0 | 1,107,374 |
| 2020-04-15 | 2018 | George A. Cardoza President of Pharma Services | 370,000 | 0 | 0 | 194,364 | 0 | 1,056,522 |
| 2020-04-15 | 2017 | George A. Cardoza President of Pharma Services | 352,692 | 0 | 181,750 | 80,000 | 0 | 1,107,109 |
| 2020-04-15 | 2019 | Robert J. Shovlin President of Clinical Services | 400,000 | 0 | 214,502 | 280,000 | 3,000 | 1,284,099 |
| 2019-04-22 | 2017 | Sharon A. Virag Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-22 | 2018 | Sharon A. Virag Chief Financial Officer | 298,462 | 120,000 | 0 | 190,000 | 0 | 1,093,562 |
| 2019-04-22 | 2016 | George A. Cardoza President of Pharma Services | 293,077 | 0 | 0 | 120,000 | 0 | 913,357 |
| 2019-04-22 | 2016 | William B. Bonello Chief Strategy and Corp Development Officer Director, Investor Relations | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-22 | 2018 | Douglas M. VanOort Chief Executive Officer & Chairman of the Board | 641,923 | 0 | 650,006 | 774,000 | 3,000 | 3,347,219 |
| 2019-04-22 | 2017 | Douglas M. VanOort Chief Executive Officer & Chairman of the Board | 616,346 | 0 | 1,432,495 | 200,000 | 3,000 | 3,483,508 |
| 2019-04-22 | 2016 | Douglas M. VanOort Chief Executive Officer & Chairman of the Board | 600,000 | 0 | 0 | 310,950 | 26,077 | 2,119,006 |
| 2019-04-22 | 2018 | Lawrence M. Weiss Chief Scientific Officer | 571,519 | 100,000 | 0 | 32,276 | 0 | 855,895 |
| 2019-04-22 | 2017 | Lawrence M. Weiss Chief Scientific Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-22 | 2016 | Lawrence M. Weiss Chief Scientific Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-22 | 2017 | William B. Bonello Chief Strategy and Corp Development Officer Director, Investor Relations | 0 | 0 | 0 | 0 | 0 | 0 |
| 2019-04-22 | 2018 | William B. Bonello Chief Strategy and Corp Development Officer Director, Investor Relations | 337,692 | 0 | 0 | 174,375 | 0 | 820,145 |
| 2019-04-22 | 2016 | Robert J. Shovlin President of Clinical Services | 335,962 | 0 | 0 | 115,000 | 9,731 | 960,973 |
| 2019-04-22 | 2017 | Robert J. Shovlin President of Clinical Services | 350,000 | 0 | 363,500 | 95,000 | 3,000 | 1,304,167 |
| 2019-04-22 | 2018 | Robert J. Shovlin President of Clinical Services | 375,385 | 0 | 0 | 212,756 | 3,000 | 1,328,739 |
| 2019-04-22 | 2017 | George A. Cardoza President of Pharma Services | 352,692 | 0 | 181,750 | 80,000 | 0 | 1,107,109 |
| 2019-04-22 | 2018 | George A. Cardoza President of Pharma Services | 370,000 | 0 | 0 | 194,364 | 0 | 1,056,522 |
| 2019-04-22 | 2016 | Sharon A. Virag Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2018-04-20 | 2017 | Robert J. Shovlin | 350,000 | 0 | 363,500 | 95,000 | 3,000 | 1,304,167 |
| 2018-04-20 | 2017 | Steven G. Brodie, PHD | 335,000 | 0 | 0 | 47,500 | 0 | 505,667 |
| 2018-04-20 | 2017 | Douglas M. VanOort | 616,346 | 0 | 1,432,495 | 200,000 | 3,000 | 3,483,508 |
| 2018-04-20 | 2017 | George A. Cardoza | 352,692 | 0 | 181,750 | 80,000 | 0 | 1,107,109 |
| 2018-04-20 | 2017 | Maher Albitar, MD Chief Medical Officer | 0 | 0 | 145,400 | 106,568 | 600,000 | 1,344,635 |
| 2018-04-20 | 2016 | Maher Albitar, MD Chief Medical Officer | 0 | 0 | 0 | 195,720 | 571,923 | 1,267,923 |
| 2018-04-20 | 2015 | Maher Albitar, MD Chief Medical Officer | 0 | 0 | 0 | 150,000 | 460,000 | 1,793,537 |
| 2017-04-25 | 2014 | Robert J. Shovlin President of Clinical Services | 68,750 | 0 | 0 | 21,450 | 0 | 593,125 |
| 2017-04-25 | 2016 | Steven G. Brodie | 313,654 | 0 | 0 | 45,000 | 12,885 | 621,679 |
| 2017-04-25 | 2016 | Douglas M. VanOort | 600,000 | 0 | 0 | 310,950 | 26,077 | 2,119,006 |
| 2017-04-25 | 2016 | George A. Cardoza Chief Financial Officer | 293,077 | 0 | 0 | 120,000 | 0 | 913,357 |
| 2017-04-25 | 2015 | George A. Cardoza Chief Financial Officer | 270,000 | 100,000 | 0 | 80,925 | 0 | 810,665 |
| 2017-04-25 | 2014 | George A. Cardoza Chief Financial Officer | 266,539 | 0 | 0 | 84,258 | 0 | 385,397 |
| 2017-04-25 | 2016 | Dr. Maher Albitar Chief Medical Officer | 0 | 0 | 0 | 195,720 | 571,923 | 1,267,923 |
| 2017-04-25 | 2015 | Dr. Maher Albitar Chief Medical Officer | 0 | 0 | 0 | 150,000 | 460,000 | 1,793,537 |
| 2017-04-25 | 2014 | Dr. Maher Albitar Chief Medical Officer | 0 | 0 | 0 | 141,287 | 453,077 | 669,984 |
| 2017-04-25 | 2016 | Robert J. Shovlin President of Clinical Services | 335,962 | 0 | 0 | 115,000 | 9,731 | 960,973 |
| 2017-04-25 | 2015 | Robert J. Shovlin President of Clinical Services | 331,250 | 0 | 0 | 100,000 | 9,816 | 441,066 |
| 2016-04-29 | 2015 | Dr. Maher Albitar Chief Medical Officer | 0 | 0 | 0 | 150,000 | 460,000 | 1,793,537 |
| 2016-04-29 | 2013 | George A. Cardoza Chief Financial Officer | 245,500 | 0 | 0 | 64,290 | 0 | 309,790 |
| 2016-04-29 | 2014 | George A. Cardoza Chief Financial Officer | 266,539 | 0 | 0 | 84,258 | 0 | 385,397 |
| 2016-04-29 | 2015 | George A. Cardoza Chief Financial Officer | 270,000 | 100,000 | 0 | 80,925 | 0 | 810,665 |
| 2016-04-29 | 2013 | Douglas M. VanOort Chief Executive Officer and Chairman of the Board | 425,000 | 0 | 0 | 139,429 | 0 | 564,429 |
| 2016-04-29 | 2014 | Douglas M. VanOort Chief Executive Officer and Chairman of the Board | 441,346 | 0 | 381,250 | 305,157 | 0 | 1,127,753 |
| 2016-04-29 | 2015 | Douglas M. VanOort Chief Executive Officer and Chairman of the Board | 475,000 | 600,000 | 0 | 206,447 | 1,385 | 1,282,832 |
| 2016-04-29 | 2014 | Steven C. Jones Executive Vice President, Finance | 0 | 100,000 | 0 | 77,500 | 257,500 | 435,000 |
| 2016-04-29 | 2015 | Steven C. Jones Executive Vice President, Finance | 0 | 500,000 | 0 | 78,910 | 261,750 | 1,706,848 |
| 2016-04-29 | 2013 | Steven C. Jones Executive Vice President, Finance | 0 | 25,000 | 0 | 51,894 | 250,001 | 326,895 |
| 2016-04-29 | 2013 | Robert J. Shovlin Chief Growth Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2016-04-29 | 2014 | Robert J. Shovlin Chief Growth Officer | 68,750 | 0 | 0 | 21,450 | 0 | 593,125 |
| 2016-04-29 | 2015 | Robert J. Shovlin Chief Growth Officer | 331,250 | 0 | 0 | 100,000 | 9,816 | 441,066 |
| 2016-04-29 | 2013 | Steven A. Ross Chief Information Officer | 156,923 | 0 | 0 | 32,580 | 24,840 | 406,594 |
| 2016-04-29 | 2014 | Steven A. Ross Chief Information Officer | 254,250 | 0 | 0 | 74,446 | 0 | 328,696 |
| 2016-04-29 | 2015 | Steven A. Ross Chief Information Officer | 256,760 | 0 | 0 | 70,000 | 1,385 | 508,015 |
| 2016-04-29 | 2013 | Dr. Maher Albitar Chief Medical Officer | 0 | 0 | 0 | 100,140 | 435,385 | 535,525 |
| 2016-04-29 | 2014 | Dr. Maher Albitar Chief Medical Officer | 0 | 0 | 0 | 141,287 | 453,077 | 669,984 |
| 2015-05-19 | 2012 | George A. Cardoza Chief Financial Officer | 233,853 | 65,000 | 0 | 0 | 0 | 333,768 |
| 2015-05-19 | 2014 | Steven A. Ross | 254,250 | 68,000 | 0 | 6,446 | 0 | 394,189 |
| 2015-05-19 | 2014 | Dr. Maher Albitar | 0 | 131,000 | 0 | 10,287 | 440,000 | 830,979 |
| 2015-05-19 | 2013 | George A. Cardoza Chief Financial Officer | 245,500 | 60,000 | 0 | 4,590 | 0 | 325,806 |
| 2015-05-19 | 2014 | George A. Cardoza Chief Financial Officer | 266,539 | 77,500 | 0 | 6,758 | 0 | 368,644 |
| 2015-05-19 | 2014 | Douglas M. VanOort | 441,346 | 293,968 | 91,000 | 11,189 | 0 | 928,986 |
| 2015-05-19 | 2014 | Steven C. Jones | 0 | 177,500 | 0 | 5,821 | 257,500 | 440,821 |
| 2015-05-19 | 2012 | Robert J. Shovlin Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2015-05-19 | 2013 | Robert J. Shovlin Chief Operating Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2015-05-19 | 2014 | Robert J. Shovlin Chief Operating Officer | 68,750 | 20,000 | 0 | 1,450 | 0 | 150,073 |
| 2014-04-30 | 2013 | Steven C. Jones | 0 | 72,500 | 0 | 4,394 | 250,000 | 326,894 |
| 2014-04-30 | 2013 | Douglas M. VanOort | 425,000 | 132,000 | 0 | 7,429 | 0 | 719,773 |
| 2014-04-30 | 2013 | George A. Cardoza Chief Financial Officer | 245,500 | 60,000 | 0 | 4,590 | 0 | 325,806 |
| 2014-04-30 | 2012 | George A. Cardoza Chief Financial Officer | 233,853 | 65,000 | 0 | 0 | 0 | 337,768 |
| 2014-04-30 | 2011 | George A. Cardoza Chief Financial Officer | 221,423 | 65,000 | 0 | 0 | 0 | 342,555 |
| 2014-04-30 | 2013 | Dr. Maher Albitar | 0 | 92,500 | 0 | 7,640 | 431,570 | 1,014,229 |
| 2014-04-30 | 2013 | Robert P. Gasparini | 286,603 | 45,000 | 0 | 4,864 | 0 | 336,467 |
| 2013-05-08 | 2011 | Douglas M. VanOort Chief Executive Officer and Chairman of the Board | 325,000 | 175,000 | 0 | 0 | 0 | 586,274 |
| 2013-05-08 | 2012 | Dr. Maher Albitar Chief Medical Officer | 0 | 98,775 | 0 | 0 | 404,978 | 790,102 |
| 2013-05-08 | 2011 | Dr. Maher Albitar Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| 2013-05-08 | 2012 | Robert P. Gasparini Chief Scientific Officer | 282,417 | 69,500 | 0 | 0 | 0 | 351,917 |
| 2013-05-08 | 2011 | Robert P. Gasparini Chief Scientific Officer | 258,333 | 57,700 | 0 | 0 | 0 | 337,725 |
| 2013-05-08 | 2012 | Douglas M. VanOort Chief Executive Officer and Chairman of the Board | 410,000 | 203,000 | 0 | 0 | 0 | 848,497 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
